Evidence map›Paper›PMID 32048692›Full record

ArticleChemical communications (Cambridge, England)2020

The affinity of RSK for cylitol analogues of SL0101 is critically dependent on the B-ring C-4'-hydroxy.

Yu Li, Pedro Seber, Eric B Wright, Sharia Yasmin, Deborah A Lannigan, George A O'Doherty

Open access · greenAbstract read
In one paragraph

Article in Chemical communications (Cambridge, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Therapeutic targeting of p90 ribosomal S6 kinase.Frontiers in cell and developmental biology · 2023
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Yu LiDepartment of Chemistry and Chemical Biology, Northeastern University, Boston, MA 02115, USA. g.odoherty@neu.edu.ORCID http://orcid.org/0000-0001-9315-8525
Pedro SeberDepartments of Pathology, Microbiology & Immunology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA. deborah.lannigan@vumc.org.
Eric B WrightBiomedical Engineering, Nashville, TN 37232, USA.
Sharia YasminCell & Developmental Biology, Nashville, TN 37232, USA.
Deborah A LanniganDepartments of Pathology, Microbiology & Immunology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA. deborah.lannigan@vumc.org and Biomedical Engineering, Nashville, TN 37232, USA and Cell & Developmental Biology, Nashville, TN 37232, USA.ORCID http://orcid.org/0000-0001-8380-9240
George A O'DohertyDepartment of Chemistry and Chemical Biology, Northeastern University, Boston, MA 02115, USA. g.odoherty@neu.edu.ORCID http://orcid.org/0000-0002-1699-2249
Nashville Oncology Associates · USNortheastern University · USVanderbilt University · US

Funding

RSK2 in Estrogen Receptor Positive (ER+) Breast CancerR01CA213201 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI LANNIGAN, DEBORAH, SULIKOWSKI, GARY ALLEN · 2018 to 2022
$1.8M
Apramycin scaffold exploration using novel glycochemistry and SAR studies to enhance activity against Acinetobacter baumannii and other multidrug-resistant Gram-negative pathogensR21AI142040 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI KIRBY, JAMES E, O'DOHERTY, GEORGE A · 2019 to 2020
$476k
Fusidic acid derivatization to enhance entry into Gram-negative pathogensR21AI146485 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI KIRBY, JAMES E, O'DOHERTY, GEORGE A · 2019 to 2020
$475k
Targeted modification of the apramycin 2-deoxystreptamine ring to block aminoglycoside modifying enzyme-based inactivation and enhance potency against multidrug-resistant Gram-negative pathogensR03AI144196 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI KIRBY, JAMES E, O'DOHERTY, GEORGE A · 2019 to 2020
$183k
NCI NIH HHS R01 CA213201NIAID NIH HHS R03 AI144196NIAID NIH HHS R21 AI142040NIAID NIH HHS R21 AI146485
6 · The paper itself

Abstract

Five cyclitol analogues of SL0101 with variable substitution at the C-4' position (i.e., OH, Cl, F, H, OMe) were synthesized. The series of analogues were evaluated for their ability to inhibit p90 ribosomal S6 kinase (RSK) activity. The study demonstrated the importance of the B-ring C-4' hydroxy group for RSK1/2 inhibition.

Identifiers

PMID32048692
PMCPMC7285658
OpenAlexW3003713140

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.